A 26 week randomised, controlled, open label, multicentre, multinational, three-arm, treat to target trial comparing efficacy and safety of three different dosing regimens of either Soluble Insulin Basal Analogue (SIBA) or insulin glargine with or without combination with OAD treatment, in subjects with type 2 diabetes mellitus.

Trial Profile

A 26 week randomised, controlled, open label, multicentre, multinational, three-arm, treat to target trial comparing efficacy and safety of three different dosing regimens of either Soluble Insulin Basal Analogue (SIBA) or insulin glargine with or without combination with OAD treatment, in subjects with type 2 diabetes mellitus.

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Jun 2016

At a glance

  • Drugs Insulin degludec (Primary) ; Antihyperglycaemics; Insulin glargine
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 21 Aug 2010 Status changed from recruiting to completed as reported by United Kingdom Clinical Research Network record.
    • 26 Jul 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top